Atypical Course of SarsCov-2 Infection in a Patient with Multiple Myeloma Treated with Autologous Stem Cell Transplantation
,
Abstract
Covid-19 infection has more relevant consequences in frail and comorbid patients but little is known about its course in patients with hematologic malignancies. In this report we would like to present the case of a patient with multiple myeloma treated with recent autologous bone marrow stem cell transplantation and affected by Covid-19 pneumonia, presenting with a possible reinfection or an extremely long viral shedding.
1. Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population- based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107-13.
2. Schütt P, Brandhorst D, Stellberg W, et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma. 2006;47(8):1570-82.
3. Hassan IA, Chopra R, Swindell R, et al. Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience1. Bone Marrow Transplant. 2003;32(1):73-7.
4. Roghmann M, Ball K, Erdman D, et al. Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation. Bone Marrow Transplant. 2003;32(11):1085-1088.
5. Baang JH, Smith C, Mirabelli C, et al. Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient. J Infect Dis. 2021;223(1):23-27.
6. Tillett RL, Sevinsky JR, Hartley PD, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2021;21(1):52-58.
7. Porrata LF, Litzow MR, Markovic SN. Immune reconstitution after autologous hematopoietic stem cell transplantation. Mayo Clin Proc. 2001;76(4):407-412.
8. Bosch M, Khan FM, Storek J. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol. 2012;19(4):324-35.
9. Steingrimsdottir H, Gruber A, Björkholm M, et al. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications. Haematologica. 2000;85(8):832-8.
10. Ardura M, Hartley D, Dandoy Cet al. Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices. Biol Blood Marrow Transplant. 2020;26(7):e147-e160.
11. Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. N Engl J Med. 2020;383(26):2586-2588.
12. Avanzato VA, Matson MJ, Seifert SN, et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell. 2020;183(7):1901-1912.e9.
2. Schütt P, Brandhorst D, Stellberg W, et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma. 2006;47(8):1570-82.
3. Hassan IA, Chopra R, Swindell R, et al. Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience1. Bone Marrow Transplant. 2003;32(1):73-7.
4. Roghmann M, Ball K, Erdman D, et al. Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation. Bone Marrow Transplant. 2003;32(11):1085-1088.
5. Baang JH, Smith C, Mirabelli C, et al. Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient. J Infect Dis. 2021;223(1):23-27.
6. Tillett RL, Sevinsky JR, Hartley PD, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2021;21(1):52-58.
7. Porrata LF, Litzow MR, Markovic SN. Immune reconstitution after autologous hematopoietic stem cell transplantation. Mayo Clin Proc. 2001;76(4):407-412.
8. Bosch M, Khan FM, Storek J. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol. 2012;19(4):324-35.
9. Steingrimsdottir H, Gruber A, Björkholm M, et al. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications. Haematologica. 2000;85(8):832-8.
10. Ardura M, Hartley D, Dandoy Cet al. Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices. Biol Blood Marrow Transplant. 2020;26(7):e147-e160.
11. Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. N Engl J Med. 2020;383(26):2586-2588.
12. Avanzato VA, Matson MJ, Seifert SN, et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell. 2020;183(7):1901-1912.e9.
| Files | ||
| Issue | Vol 17, No 2 (2023) | |
| Section | Case Report(s) | |
| DOI | https://doi.org/10.18502/ijhoscr.v17i2.12652 | |
| Keywords | ||
| Covid-19 Multiple myeloma; Hematopoietic stem cell transplantation | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Isaia G, Valerio S, Oliva S, Brunetti E, Bo M. Atypical Course of SarsCov-2 Infection in a Patient with Multiple Myeloma Treated with Autologous Stem Cell Transplantation. Int J Hematol Oncol Stem Cell Res. 2023;17(2):129-132.
